Home Page News Statistics API Review Formulation Monthly Im&Ex report All Information
     
Keyword:
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Conference on ...
Information Release...
Internationalization&nbs...
Welcome to Pro...
Healthoo.com Carbap...
APIs Innovation&nbs...
China Import Export Statistics Report In...
API Export Price by ...
Tylosin Bulk Drug Export&...
China Monthly Export Stat...
China Monthly Export Stat...
China Monthly Export Stat...
Your position:www.healthoo.com >> EN >> Formulation
ADDRESS THE INDUSTRY’S CONCERN2023-09-20
Hansoh Pharmas Zolbetuximab Receives BLA Acceptance for Gastric Cancer Treatment in China2023-09-01
GlaxoSmithKline Pharmaceuticals Reports 11% Rise in Q1 Profit Driven by Strong Demfor Vaccines2023-08-11
GLP-1 Weight Loss Drugs: A Review of Current Drugs Developments2023-08-11
Hansoh Pharmas Zolbetuximab Receives BLA Acceptance for Gastric Cancer Treatment in China2023-08-11
Betta Pharmaceuticals CFT8919 approved for clinical trials in the United States2023-07-12
Hengrui Pharmaceuticals innovative drug HRS-4357 injection has been approved for clinical use in prostate cancer2023-07-12
Nine key words & hot events in the pharmaceutical industry in 2023 H12023-07-12
Elon Musk takes ketamine for depression parties? The Controversial Use of Ketamine: A Potent Psychedelic Drug2023-07-03
Pimicotinib was approved by EMA Priority Drug Program2023-06-14
Zhaoke Ophthalmology joins forces with Eyedetec Medical2023-06-14
RemeGen ADC drug RC108 combined with PD-1 has been approved for the treatment of solid tumors in phase Ⅰb/Ⅱ clinical trial2023-06-14
Boanbiodulaglutide injection BA5101 completed phase III clinical trial2023-06-08
With annual sales of times="32".4 billion, the race is on for the first copy of this innovative drug2023-06-08
The legendary Bio-Citagiorencel reduces the risk of disease progression or death by 74%2023-06-08
Antidepressant market usher in new opportunities, see "a brother" status fall to who hand?2023-05-11
Analysis of 70 macrocyclic drugs approved by the FDA2023-05-11
$860 million market size, PDC drug development market analysis2023-05-11
Only 3 drugs have been approved! Frozen life, times="32".16 million worth of drugs2023-05-11
Enbio: Partnered with BioNTech to advance the development of next-generation antibody conjugated drugs (ADCs)2023-04-20
Cure diabetes obesity with printed materials? Novo Nordisk Introduces Cell Therapy for .6 billion2023-04-20
Multiple product indications withdrawn, FDA accelerated Approval How to reform?2023-04-20
Maxpro: Completed merger with SPAC Maxpro listed on Nasdaq2023-03-31
Meinol completed the B round financing of over 100 million yuan, continued to accelerate the overall layout of CXO industry2023-03-31
Received orphan drug recognition! Shanghai Pharmaceutical SPH4336 breakthrough liposarcoma2023-03-31
Yi Neng Pharmaceutical, A leading TCM CXO enterprise, has completed a series of financing of over 100 million yuan, enabling the modernization innovation research development of TCM2023-03-31
After 20 years of failure, Is there Hope for targeted Aβ therapy for AD?2023-03-20
$161 million! China Biopharmaceutical completes acquisition of F-star Therapeutics2023-03-10
The different paths of Chinese foreign diabetes giants: double males double bears2023-03-03
Sanofis cracked quadrivalent influenza virus vaccine, VaxigripTetra?, was approved for sale in China2023-03-03
Star ADC Therapy DS-8201 approved for market in China!2023-03-03
Star ADC Therapy DS-8201 approved for market in China!2023-03-01
1510个 页次:2/4832个/页 首页 上一页 下一页 尾页 转到:
Our Advantages of Reports
①All reports written by ourselves
②All data having original sources
③Information is the latest
④Continuous historical data
⑤Objective analysis and remark
Purchase Flow of Reports
①Confirm purchase (If necessary sign the contract)
②Transfer payment to company's bank account
③After accepting payment we email the report to clients (PDF format)
④Send the invoice
Bank account
①Beneficiary's Name:Beijing orientbit technology ltd
②Beneficiary's Account No.:110060239018002127366
③Name of bank:Bank of Communications Beijing Branch,Fuwai Sub-Branch
④Address of bank:NO7,FUWAISTREET,XICHENG DISTRICT,BEIJING,CHINA SWIFT CODE:COMMCNSHBJG
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463